ReviewBiomedicines2024
Exploring
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Type 2 Diabetes-Induced Molecular and Functional Impairment of Adipose Tissue-Derived Mesenchymal Stromal Cells (ASCs) and Interferon Gamma Priming for Enhanced Diabetic ASC-Based Therapy.Stem cell reviews and reports · 2026Article
- Psoriasis and chronic kidney disease: insights into mechanisms and novel therapeutic outlooks.International urology and nephrology · 2026Review
- An Overview of Genetics of Moyamoya: BeyondInternational journal of molecular sciences · 2026Review
- Current Insights into the Molecular Mechanisms of Intracranial Atherosclerosis and Their Therapeutic Implications.International journal of molecular sciences · 2026Review
- A STOP-Gain RNF213 Variant Causes Chorea, Stroke-Like Episodes, and Leigh Syndrome-Like Encephalopathy.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Reframing moyamoya vasculopathy within steno-occlusive disease of the circle of Willis.Frontiers in stroke · 2026Review
- Coronary artery spasm: mechanisms, risk factors, and translational strategies for precision management.Frontiers in cardiovascular medicine · 2026Review
- A ruptured de novo anastomotic aneurysm shortly after superficial temporal artery-to-middle cerebral artery bypass surgery in a patient with moyamoya disease: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Multisystemic Impact of RNF213 Arg4810Lys: A Comprehensive Review of Moyamoya Disease and Associated Vasculopathies.International journal of molecular sciences · 2025Review
- RNF213-Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells.Genes to cells : devoted to molecular & cellular mechanisms · 2025Article
- A Rare Case of Moyamoya Disease in Infancy: Complexities in Post-stroke Neurorehabilitation.Cureus · 2025Article
- Recent Advances in Genetics of Moyamoya Disease: Insights into the Different Pathogenic Pathways.International journal of molecular sciences · 2025Review
- A revised concept of moyamoya vasculopathy: developmental origins and genetic insights.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in stroke genetics have highlighted the critical role of rare genetic variants in cerebrovascular diseases, with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.